Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
P53611
UPID:
PGTB2_HUMAN
Alternative names:
Geranylgeranyl transferase type II subunit beta; Rab geranyl-geranyltransferase subunit beta; Rab geranylgeranyltransferase subunit beta; Type II protein geranyl-geranyltransferase subunit beta
Alternative UPACC:
P53611; Q92697
Background:
Geranylgeranyl transferase type-2 subunit beta, also known as Rab geranylgeranyltransferase subunit beta, plays a crucial role in the post-translational modification of Rab proteins. It catalyzes the transfer of a geranylgeranyl group to Rab proteins, which is essential for their proper function in intracellular trafficking.
Therapeutic significance:
Understanding the role of Geranylgeranyl transferase type-2 subunit beta could open doors to potential therapeutic strategies.